Aviat Networks, Inc. (NASDAQ:AVNW) shares advanced 3.23% in last trading session and ended the day at $0.64. AVNW Gross Margin is 23.00% and its has a return on assets of -9.90%. Aviat Networks, Inc. (NASDAQ:AVNW) quarterly performance is -8.57%.
On 12 April, Aviat Networks, Inc. (NASDAQ:AVNW) provided updates on its corporate realignment initiatives and outlined aggressive actions to drive to profitability.
RTI Surgical Inc. (NASDAQ:RTIX) ended the last trading day at $4.12. Company weekly volatility is calculated as 4.15% and price to cash ratio as 18.72. RTI Surgical Inc. (NASDAQ:RTIX) showed a weekly performance of 3.26%.
RTI Surgical Inc. (NASDAQ:RTIX) announced that it will be distributing proxy material and the following letter to RTI stockholders urging them to protect their investment in RTI and vote the WHITE proxy card FOR the election of Peter F. Gearen, Brian K. Hutchison, Thomas A. McEachin, Jonathon M. Singer, Paul G. Thomas, Nicholas J. Valeriani and Shirley A. Weis, RTI’s highly qualified director nominees, at the Company’s upcoming annual meeting of stockholders on May 26, 2016.
On 19 April, Enersis Americas S.A. (NYSE:ENI) shares advanced 4.31% and was closed at $14.27. ENI EPS growth in last 5 year was -17.40%. Enersis Americas S.A. (NYSE:ENI) year to date (YTD) performance is 18.42%.
Enersis Americas S.A. (NYSE:ENI) changed the record date for determining when its investors will be entitled to receive one share of Enersis Chile stock for each share of Enersis Americas held to April 20 from the previously announced April 14.
Loxo Oncology, Inc. (NASDAQ:LOXO) shares fell -8.11% in last trading session and ended the day at $24.12. LOXO has a return on assets of -30.80%. Loxo Oncology, Inc. (NASDAQ:LOXO) quarterly performance is 22.37%.
Loxo Oncology, Inc. (NASDAQ:LOXO) said it has published a manuscript describing a partial response in the first patient enrolled in the pediatric phase 1 dose-escalation trial of LOXO-101 for the treatment of refractory infantile fibrosarcoma. The company said that after 28 days, imaging of the brain and neck of a 16-month old female patient showed a tumor regression of more than 90% from baseline.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) caters to the Healthcare space. Its weekly performance is 17.61%. On the last day of trading company shares ended up at $3.64. Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) distance from 50-day simple moving average (SMA50) is -0.91%.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) announced the U.S. Food and Drug Administration (FDA) has determined that the company’s New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC) is sufficiently complete to permit a substantive review. The FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.
Leave a Reply